Protagen Sells Protein Services Subsidiary in Shift Toward Focus on Dx Development | GenomeWeb

NEW YORK (GenomeWeb News) – German biotech firm Protagen said today that it has sold its subsidiary Protagen Protein Services to venture capital fund Zukunftsfond Heilbronn.

The sale will provide Protagen with funds to support its diagnostic development efforts, the company said. Financial and other terms of the deal were not disclosed.

Spun out as a 100 percent subsidiary of Protagen in January 2012, Protagen Protein Services offers a variety of protein analysis services aimed at academic labs as well as biopharmaceutical and biosimilars work.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.